HeraMED Ltd. AI Stock Analysis
Want to see AU:HMD full AI Analyst Report?
HeraMED Ltd. (HMD) AI Stock Analysis
HeraMED Ltd.
(ASX:HMD)
The overall score is severely depressed, driven primarily by the company's deteriorating financial performance, including a collapse in gross margin and persistent losses. Technical trends confirm sustained bearish momentum with the stock trading below all major moving averages. The negative P/E ratio and lack of dividend yield further diminish any investment case, leaving the stock in a highly speculative and high-risk position.
HeraMED Ltd. (HMD) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 40.55M
- Dividend Yield
- ―
- Average Volume (3M)
- 756.33K
- Price to Earnings (P/E)
- -10.6
- Beta (1Y)
- 1.17
- Revenue Growth
- -52.35%
- EPS Growth
- 40.38%
- Country
- Australia
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
HeraMED Ltd. Business Overview & Revenue Model
Company Description
HeraMED Limited and its associated entities are dedicated to the design, production, and sale of at-home fetal heart rate monitors and comprehensive pregnancy monitoring systems. These solutions are offered to consumers throughout Australia, Europe,...
HeraMED Ltd. Financial Statement Overview
Summary
Financial health is critically weak. Revenue is declining sharply, gross margin has collapsed to 0%, and the company remains deeply unprofitable with negative cash flows. The only mitigating factor is a debt-free balance sheet, but the low equity base offers minimal cushion against ongoing losses.
Income Statement
15Very NegativeBalance Sheet
25NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 102.69K | 195.77K | 225.49K | 413.19K | 215.81K | 83.68K |
| Gross Profit | 95.42K | 99.78K | 135.29K | 248.12K | -214.69K | -219.50K |
| EBITDA | -2.21M | -2.56M | -3.15M | -3.97M | -2.83M | -3.67M |
| Net Income | -2.36M | ― | -3.40M | -4.50M | -4.88M | -5.71M |
Balance Sheet | ||||||
| Total Assets | 2.15M | 994.94K | 2.78M | 2.01M | 4.19M | 4.57M |
| Cash, Cash Equivalents and Short-Term Investments | 2.03M | 914.65K | 3.13M | 723.29K | 2.64M | 3.55M |
| Total Debt | 0 | 282.39K | 815.96K | 209.37K | 179.53K | 3.41M |
| Total Liabilities | 403.51K | 559.96K | 1.06M | 1.55M | 1.30M | 4.13M |
| Stockholders Equity | 1.75M | 621.27K | 1.72M | 466.70K | 2.88M | -105.66K |
Cash Flow | ||||||
| Free Cash Flow | -2.18M | -2.44M | -2.98M | -5.57M | -3.20M | -3.20M |
| Operating Cash Flow | -2.18M | -2.44M | -2.98M | -5.57M | -2.52M | -3.12M |
| Investing Cash Flow | 0 | 0 | 0 | -2,046 | -690.78K | -85.43K |
| Financing Cash Flow | 3.54M | 1.27M | 6.88M | 2.96M | 2.54M | 4.88M |
HeraMED Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HMD, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 45.98 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HMD.
HeraMED Ltd. Peers Comparison
Overall Rating
AU:RMD84Outperform
AU:CMP54Neutral
AU:AT144Neutral
AU:UCM43Neutral
AU:IPD39Underperform
AU:HMD38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 84Outperform | AUD 50.09B | 21.51 | 25.14% | 0.98% | 1.54% | 4.43% | |
| 54Neutral | AUD 46.94M | 209.09 | 0.93% | ― | 18.54% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | AUD 10.83M | -2.86 | -48.97% | ― | 40.65% | 45.45% | |
| 43Neutral | AUD 3.12M | -1.56 | -1788.57% | ― | -52.22% | 44.79% | |
| 39Underperform | AUD 18.33M | -0.43 | -259.31% | ― | 14.85% | -1.74% | |
| 38Underperform | AUD 40.55M | -10.59 | -198.77% | ― | -52.35% | 40.38% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:HMD | HeraMED Ltd. | 0.04 | -0.00 | -5.41% | |
| AU:CMP | Compumedics Limited | 0.23 | -0.10 | -28.79% | |
| AU:IPD | Impedimed Limited | 0.01 | -0.02 | -60.00% | |
| AU:UCM | Uscom Limited | 0.01 | 0.00 | 0.00% | |
| AU:AT1 | Atomo Diagnostics Ltd. | 0.01 | -0.02 | -56.67% | |
| AU:RMD | Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh | 35.44 | -2.79 | -7.29% |
HeraMED Ltd. Corporate Events
HeraMED Wins People’s Choice Award at Garmin Health Awards
HeraMED won the People’s Choice Award at the 2026 Garmin Health Awards in Bangkok, selected from six finalists among 113 applications spanning 31 countries. The award recognises its HeraCARE platform and its focus on connected, personalised women’s h...
HeraMED Secures First Major U.S. SaaS Rollout With Lee Health
HeraMED has advanced its U.S. commercialisation strategy by moving its Digital Pregnancy Journey program with Lee Health from a six-month pilot into a paid, recurring SaaS deployment. The initial US$317,200 contract covers 200 mothers and includes He...
HeraMED Secures Full-Scale Digital Maternity Rollout with US Health System Lee Health
Lee Health, a major non-profit healthcare system in Southwest Florida that delivers more than 8,000 babies annually, has approved the full commercial deployment of HeraMED’s digital maternity solution after a successful six-month pilot. The program,...
HeraMED Shares Halted Ahead of Material Commercial Deployment News
HeraMED Ltd. has requested and received a trading halt on its ordinary shares from the ASX, with the suspension effective immediately and expected to last until either the start of normal trading on 17 September 2026 or the release of a pending annou...
HeraMED Issues 3.3 Million Unquoted Performance Rights Under Incentive Plan
HeraMED Ltd. has notified the market of the issue of 3.3 million unquoted performance rights under its employee incentive scheme, dated 14 August 2026. The new awards, which are not intended to be quoted on the ASX, underscore the company’s use of eq...
HeraMED Narrows Half-Year Loss as Revenue Slumps but Asset Backing Improves
HeraMED Limited reported a sharp contraction in revenue for the half-year ended 30 June 2026, with income from ordinary activities falling 72.5% to $38,325, while its net loss narrowed 29.2% to $1.6 million compared with the prior corresponding perio...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026
